Literature DB >> 710412

The binding of low-affinity and high-affinity heparin to antithrombin. Fluorescence studies.

B Nordenman, A Danielsson, I Björk.   

Abstract

The interaction between antithrombin and two forms of heparin, differing in their affinity for the matrix-linked protein, has been studied by fluorescence. The binding of the high-affinity heparin fraction to antithrombin leads to activation of the inhibitor, allowing it to react more rapidly with a number of serine proteases of the coagulation cascade. The interaction with the low-affinity heparin fraction, however, has considerably less influence on this inhibition rate. The binding of either fraction to antithrombin was found to result in an increase of the tryptophan fluorescence of the protein. This increase was much larger for high-affinity heparin than for low-affinity heparin, suggesting a different mode of binding of the two fractions to the protein. The fluorescence enhancement caused by high-affinity heparin is consistent with a conformational change of antithrombin related to its activation. Only the fluorescence enhancement observed on the binding of high-affinity heparin was of a sufficient magnitude to allow quantitative studies. These showed high-affinity heparin to bind to antithrombin with a stoichiometry of about one and with a binding constant at physiological ionic strength of about 8 X 10(7) M-1. At higher ionic strengths, however, the affinity decreased markedly.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 710412     DOI: 10.1111/j.1432-1033.1978.tb12567.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  17 in total

1.  Decreased affinity of recombinant antithrombin for heparin due to increased glycosylation.

Authors:  I Björk; K Ylinenjärvi; S T Olson; P Hermentin; H S Conradt; G Zettlmeissl
Journal:  Biochem J       Date:  1992-09-15       Impact factor: 3.857

2.  Effect of oversulphated chondroitin and dermatan sulphate upon thrombin and factor Xa inactivation by antithrombin III or heparin cofactor II.

Authors:  M F Scully; V Ellis; N Seno; V V Kakkar
Journal:  Biochem J       Date:  1988-09-01       Impact factor: 3.857

3.  Formation, characterization and detection of a ternary complex between S protein, thrombin and antithrombin III in serum.

Authors:  K T Preissner; L Zwicker; G Müller-Berghaus
Journal:  Biochem J       Date:  1987-04-01       Impact factor: 3.857

4.  Fluorescent reporters of thrombin, heparin cofactor II, and heparin binding in a ternary complex.

Authors:  Ingrid M Verhamme
Journal:  Anal Biochem       Date:  2011-12-06       Impact factor: 3.365

5.  Interaction of heparin with internally quenched fluorogenic peptides derived from heparin-binding consensus sequences, kallistatin and anti-thrombin III.

Authors:  Daniel C Pimenta; Iseli L Nantes; Eduardo S de Souza; Bernard Le Bonniec; Amando S Ito; Ivarne L S Tersariol; Vitor Oliveira; Maria A Juliano; Luiz Juliano
Journal:  Biochem J       Date:  2002-09-01       Impact factor: 3.857

Review 6.  Mechanism of the anticoagulant action of heparin.

Authors:  I Björk; U Lindahl
Journal:  Mol Cell Biochem       Date:  1982-10-29       Impact factor: 3.396

7.  Binding to antithrombin of heparin fractions with different molecular weights.

Authors:  A Danielsson; I Björk
Journal:  Biochem J       Date:  1981-02-01       Impact factor: 3.857

8.  Elimination of glycosylation heterogeneity affecting heparin affinity of recombinant human antithrombin III by expression of a beta-like variant in baculovirus-infected insect cells.

Authors:  E Ersdal-Badju; A Lu; X Peng; V Picard; P Zendehrouh; B Turk; I Björk; S T Olson; S C Bock
Journal:  Biochem J       Date:  1995-08-15       Impact factor: 3.857

Review 9.  Sulfated Non-Saccharide Glycosaminoglycan Mimetics as Novel Drug Discovery Platform for Various Pathologies.

Authors:  Daniel K Afosah; Rami A Al-Horani
Journal:  Curr Med Chem       Date:  2020       Impact factor: 4.530

Review 10.  Heparan sulfate 3-O-sulfation: a rare modification in search of a function.

Authors:  Bryan E Thacker; Ding Xu; Roger Lawrence; Jeffrey D Esko
Journal:  Matrix Biol       Date:  2013-12-19       Impact factor: 11.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.